Literature DB >> 1759823

Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria.

P Heisig1, B Wiedemann.   

Abstract

The gyrA genotypes of ciprofloxacin-resistant clinical isolates of Escherichia coli (n = 3), Klebsiella pneumoniae (n = 4), Providencia stuartii (n = 2), Pseudomonas aeruginosa (n = 1), and Acinetobacter calcoaceticus (n = 1) were analyzed in a dominance test. This test is based on the dominance of a wild-type gyrA gene (gyrA+) over the quinolone resistance allele (gyrA) in a heterodiploid strain. Plasmid pBP515, developed to carry the gyrA+ gene of E. coli K-12 on a broad-host-range vector derived from pRSF1010, was used to obtain heterodiploid strains. Plasmid pBP515 encodes kanamycin and gentamicin resistance and is transferable via mobilization by a pRP1-derived helper plasmid (pRP1H) to strains of several gram-negative species. After the introduction of pBP515, single-cell MICs (as measured by reduction of the viable cell count) of ciprofloxacin and nalidixic acid decreased by 4- to greater than 8,000-fold for all strains tested, and 8 of the 11 strains regained ciprofloxacin susceptibilities similar to those of the respective wild types. The results indicate that (i) high-level fluoroquinolone resistance in clinical isolates of E. coli, K. pneumoniae, P. aeruginosa, and A. calcoaceticus can result from mutational alteration of the gyrA gene, and (ii) gyrA mutations are involved in high levels of fluoroquinolone resistance in P. stuartii. Additional mutations outside the gyrA locus may contribute to resistance in K. pneumoniae and P. stuartii.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1759823      PMCID: PMC245320          DOI: 10.1128/AAC.35.10.2031

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

1.  Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme.

Authors:  A Sugino; C L Peebles; K N Kreuzer; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

2.  Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter.

Authors:  M López-Brea; T Alarcón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

3.  Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency.

Authors:  S Chamberland; F Malouin; H R Rabin; T Schollaardt; T R Parr; L E Bryan
Journal:  J Antimicrob Chemother       Date:  1990-06       Impact factor: 5.790

4.  Cloning and simplified purification of Escherichia coli DNA gyrase A and B proteins.

Authors:  K Mizuuchi; M Mizuuchi; M H O'Dea; M Gellert
Journal:  J Biol Chem       Date:  1984-07-25       Impact factor: 5.157

5.  Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

6.  Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.

Authors:  G J Duckworth; J D Williams
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

Review 7.  DNA topoisomerases.

Authors:  M Gellert
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

8.  Characterization of Tn2411 and Tn2410, two transposons derived from R-plasmid R1767 and related to Tn2603 and Tn21.

Authors:  J Kratz; F Schmidt; B Wiedemann
Journal:  J Bacteriol       Date:  1983-09       Impact factor: 3.490

9.  Specific-purpose plasmid cloning vectors. II. Broad host range, high copy number, RSF1010-derived vectors, and a host-vector system for gene cloning in Pseudomonas.

Authors:  M Bagdasarian; R Lurz; B Rückert; F C Franklin; M M Bagdasarian; J Frey; K N Timmis
Journal:  Gene       Date:  1981-12       Impact factor: 3.688

10.  DNA gyrase: subunit structure and ATPase activity of the purified enzyme.

Authors:  K Mizuuchi; M H O'Dea; M Gellert
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

View more
  16 in total

1.  Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli.

Authors:  S Bagel; V Hüllen; B Wiedemann; P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

Review 2.  DNA gyrase, topoisomerase IV, and the 4-quinolones.

Authors:  K Drlica; X Zhao
Journal:  Microbiol Mol Biol Rev       Date:  1997-09       Impact factor: 11.056

3.  Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center.

Authors:  W V Kern; E Andriof; M Oethinger; P Kern; J Hacker; R Marre
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 4.  Mechanisms of resistance to quinolones.

Authors:  E Cambau; L Gutmann
Journal:  Drugs       Date:  1993       Impact factor: 9.546

5.  Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.

Authors:  P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

6.  Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.

Authors:  P Heisig; R Tschorny
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

7.  Topoisomerase IV is a target of quinolones in Escherichia coli.

Authors:  A B Khodursky; E L Zechiedrich; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

8.  Clinical significance and spread of fluoroquinolone resistant uropathogens in hospitalised urological patients.

Authors:  K G Naber; W Witte; A Bauernfeind; B Wiedemann; F Wagenlehner; I Klare; P Heisig
Journal:  Infection       Date:  1994       Impact factor: 3.553

Review 9.  Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994.

Authors:  L J Piddock
Journal:  Drugs       Date:  1995       Impact factor: 9.546

10.  Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli.

Authors:  P Heisig; H Schedletzky; H Falkenstein-Paul
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.